174results about How to "Reduce systemic toxicity" patented technology

The present invention concerns CAR, CAR-T and CAR-NK constructs, preferably comprising a scFv antibody fragment against a disease-associated antigen or a hapten. More preferably, the antigen is a TAA, such as Trop-2. The constructs may be administered to a subject with a disease, such as cancer, autoimmune disease, or immune dysfunction disease, to induce an immune response against disease-associated cells. Where the constructs bind to a hapten, the subject is first treated with a hapten-conjugated antibody that binds to a disease associated antigen. Therapy may be supplemented by other treatments, such as debulking procedures (e.g., surgery, chemotherapy, radiation therapy) or coadministration of other agents. More preferably, administration of the construct is preceded by predosing with an unconjugated antibody that binds to the same disease-associated antigen. Most preferably, an antibody against CD74 or HLA-DR is administered to reduce systemic immunotoxicity induced by the constructs.

Disclosed are water soluble compositions of paclitaxel and docetaxel formed by conjugating the paclitaxel or docetaxel to a water soluble polymer such as poly-glutamic acid, poly-aspartic acid or poly-lysine. Also disclosed are methods of using the compositions for treatment of tumors, auto-immune disorders such as rheumatoid arthritis. Other embodiments include the coating of implantable stents for prevention of restenosis.

This invention relates to the use of a composition comprising a polysaccharide and a botulinum toxin for reducing a skin wrinkle. In some embodiments, the polysaccharide comprises disaccharides. In some embodiments, the average molecular weight of a disaccharide unit of the polysaccharide is between about 345 D and about 1,000 D.

This invention is directed to substrates, materials and devices coated with a gel, foam, film, particle or composition comprising a polymei solvent and effector compounds attached thereto, processes of producing the same, and methods of use thereof, of in, inter-alia, biological applications, including preventing infection and the treatment of various diseases.

This disclosure relates to a modified α-helical bundle cytokine, with reduced activity via an α-helical bundle cytokine receptor, wherein the α-helical bundle cytokine is specifically delivered to target cells. Preferably, the α-helical bundle cytokine is a mutant, more preferably it is a mutant interferon, with low affinity to the interferon receptor, wherein the mutant interferon is specifically delivered to target cells. The targeting is realized by fusion of the modified α-helical bundle cytokine to a targeting moiety, preferably an antibody. This disclosure relates further to the use of such targeted modified α-helical bundle cytokine to treat diseases. A preferred embodiment is the use of a targeted mutant interferon, to treat diseases, preferably viral diseases and tumors.

A drug and drug delivery system may be utilized in the treatment of vascular disease. A local delivery system is coated with rapamycin or other suitable drug, agent or compound and delivered intraluminally for the treatment and prevention of neointimal hyperplasia following percutaneous transluminal coronary angiography. The local delivery of the drugs or agents provides for increased effectiveness and lower systemic toxicity.

This application relates to combination therapies including triciribine and related compounds and bortezomib and derivatives thereof analogs and compositions with reduced toxicity for the treatment and prevention of tumors, cancer, and other disorders associated with abnormal cell proliferation.

The present invention relates to one kind of vinorelbine liposome micro ball injection and its preparation process. The present invention has vinorelbine medicine in 90-98 % coated inside the oil phase and oil-water interface of liposome micro ball, reduces the clinical toxicity and irritation of vinorelbine greatly and raises its antitumor effect. The preparation of the present invention as one kind of antitumor injection has low irritation, low toxicity and high curative effect.

Lysine-spermine conjugates with a long-chain aliphatic (C₁₂-C₂₀) substituent at R₁ bind and neutralize bacterial lipopolysaccharides. These compounds reduce lethality in a murine model of lipopolysaccharide-induced shock, and may serve as novel leads for developing novel anti-lipopolysaccharide agents for the therapy of Gram-negative sepsis. These compounds are represented by the formula:

wherein X is O or H, H; R is a hydrophobic C₁₂-C₂₀ chain and Y is -NH₂ or -H; and pharmaceutically acceptable salts thereof and prodrugs thereof.

The invention relates to a novel long-circulating liposome composition and an application method thereof. The long-circulating liposome composition is mainly prepared from phospholipid, cholesterol, an electronegative material and a long-circulating material serving as main raw materials, wherein tocopheryl acetate succinate or cholesterol succinate is used as the electronegative material particularly, and tocopheryl acetate polyethylene glycol succinate (TPGS) is used as the long-circulating material particularly, so that the stability of combining the long-circulating liposome composition and medicaments is improved; the long-circulating liposome composition can be used as a carrier of anti-tumor medicaments such as paclitaxel, docetaxel and 10-hydroxycamptothecine, and simultaneously, the tolerance is improved; and when the long-circulating liposome composition is used as the medicinal carrier, the circulating time of the carried medicaments in vivo is longer than that of various carriers sold on the market obviously, and the long-circulating liposome composition has the advantages of low cost and suitability for wide popularization and application.

The subject invention provides a mechanism by which steroidal quinol compounds confer beneficial ophthalmic effects. The subject compounds possess a lipophilic-hydrophilic balance for transcorneal penetration and are readily reduced into parent phenolic A-ring steroid compounds to provide protection or treatment against various ocular symptoms and disorders. The compounds according to the subject invention appear to be highly advantageous as prodrugs to provide protection and/or treatment against ocular disorders. These prodrugs confer lipid solubility optimal for transocorneal penetration and are readily converted to endogenous reducing agents into active phenolic A-ring steroid compounds. To the extent that these prodrugs have reduced feminizing effects and systemic toxicity, they would be expected to be quite advantageous for protecting or treating the eye against ocular disorders such as cataract or glaucoma without undesired (systemic) side effects).

The topical anesthetic formulation of the present invention is typically a solution that preferably includes lidocaine, USP as the active anesthetic ingredient with benzyl alcohol and isopropyl alcohol. This invention deals with problems commonly associated with topical application of local anesthetics such as: slow onset of action; need for occlusion; messiness of creams, ointments or gels; and rapid loss of effect due to rapid systemic dispersion. The invention permits enhanced penetration of the anesthetic and thereby allows for a lesser total dosage of pharmaceutically active ingredient. The use of a lesser total dosage also decreases systemic toxicity.

The present invention discloses protocols for HER cancers that are also endocrine dependent in a manner that provides dual action by using both HER antibodies and endocrine blockers/downregulators and insures function of S-Phase cytotoxics by administration of endocrines prior to administration of the S-Phase cytotoxic.

The invention discloses an anthracycline liposome injection, including the injection and a frozen powder injection and a preparation process of the injection. The frozen liposome consists of the anthracycline or an anthracycline hydrochloride, compound neutral phospholipids, surfactant, negative-charge phospholipids, buffers, PH regulators and freezing protection agent. The preparation process includes the following steps: preparation of a hollow liposome, a homogenized liposome, an anthracycline lopsome and an anthracycline lopsome suspension; adding the freezing protection agent; constant volume; sterilization; sub-package; freezing and drying; storage, etc. The liposome injection can be preserved for 12 months under the room temperature with better stability. And the encapsulation rate can be above 95 percent and a granule diameter is between 30 and 300mm. The side effect is low and the technique is simple, thus being convenient for industrial production.

The present invention describes materials and methods related to synthetic peptides which block the secretion of neurotransmitters and induce muscle relaxation, and use of said peptides as inhibitors of neurotransmitter secretion and muscle contraction, and as inducers of muscle relaxation.

Compositions for targeting to a desired region of the brain or spinal cord include a therapeutic compound useful for the treatment of a neurodegenerative disease; a cell penetrating peptide (CPP); and a thermal targeting polypeptide (TTP).

The invention belongs to the field of biomedical polymer materials, and specifically relates to a thermally induced hydrogel containing selenium or tellurium, and a preparation method and applications thereof. The thermally induced hydrogel is composed of an amphiphilic block copolymer containing selenium or tellurium and a solvent; thermally induced gelatinization phase transformation of a water system of the amphiphilic block copolymer and the solvent can be realized with temperature increasing so as to realize spontaneous formation of a physical hydrogel, wherein the amphiphilic block copolymer containing selenium or tellurium is obtained via covalent bonding of small molecules containing selenium or tellurium with an amphiphilic block copolymer. Long-acting platinum drug gel sustained-release preparations can be obtained via coordination of the thermally induced hydrogel with platinum drugs. The long-acting platinum drug gel sustained-release preparations are capable of prolonging and adjusting release behavior of the loaded platinum antitumor drugs. Drug administration of the long-acting platinum drug gel sustained-release preparations in tumor, around tumor, or in tumor cavity can be realized via injection; in situ formation of gel is realized at body temperature, and the platinum drugs loaded via coordination bonds can be released from the gel slowly, so that administration frequency is reduced, and drug whole body toxicity is reduced. The long-acting platinum drug gel sustained-release preparations can be applied to tumor treatment at different periods.

The present invention relates to targeted microcapsules or nanocapsules comprising a skin whitening compound to target melanocytes with a peptide, which is a MC1 receptor agonist, wherein said peptide is coupled to the outer surface of the microcapsule or nanocapsule. It also relates to the use of said microcapsules or nanocapsules for the cosmetic prevention and/or cosmetic treatment of cutaneous dark spots, and to the cosmetic compositions comprising said microcapsules or nanocapsules. The invention also relates to the MC1 receptor agonist peptide coupled to the microcapsule or nanocapsule. The invention also relates to a peptide for use as skin whitening compound.